Hellmann MD, et al. Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy. IASLC 2018, abstract OA05.01.
Pembrolizumab actief bij klassiek en endemisch kaposisarcoom
apr 2022 | Bot en wekedelentumoren, Immuuntherapie